Advertisement

Role of Kappa Opioid Receptors in Symptoms of Schizophrenia: What Is the Neurobiology?

  • Anantha Shekhar
    Correspondence
    Address correspondence to Anantha Shekhar, M.D., Ph.D., Indiana Clinical and Translational Sciences Institute, Indiana University School of Medicine, 340 West 10th Street, Suite 6200, Indianapolis, IN 46202.
    Affiliations
    Department of Psychiatry, Stark Neurosciences Institute, and the Indiana Clinical and Translational Sciences Institute, Indiana University School of Medicine, Indianapolis, Indiana
    Search for articles by this author
      SEE CORRESPONDING ARTICLE ON PAGE 502
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chavkin C.
        • James I.F.
        • Goldstein A.
        Dynorphin is a specific endogenous ligand of the kappa opioid receptor.
        Science. 1982; 215: 413-415
        • Carlezon Jr., W.A.
        • Krystal A.D.
        Kappa-opioid antagonists for psychiatric disorders: From bench to clinical trials.
        Depress Anxiety. 2016; 10: 895-906
        • Browne C.A.
        • Lucki I.
        Targeting opioid dysregulation in depression for the development of novel therapeutics [published online ahead of print Apr 30].
        Pharmacol Ther. 2019;
        • Clark S.D.
        • Abi-Dargham A.
        The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: A review of the evidence.
        Biol Psychiatry. 2019; 86: 502-511
        • Roth B.L.
        • Baner K.
        • Westkaemper R.
        • Siebert D.
        • Rice K.C.
        • Steinberg S.
        • et al.
        Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist.
        Proc Natl Acad Sci U S A. 2002; 18: 11934-11939
        • Tejeda H.A.
        • Wu J.
        • Kornspun A.R.
        • Pignatelli M.
        • Kashtelyan V.
        • Krashes M.J.
        • et al.
        Pathway- and cell-specific kappa-opioid receptor modulation of excitation-inhibition balance differentially gates D1 and D2 accumbens neuron activity.
        Neuron. 2017; 93: 147-163
        • Nemeth C.L.
        • Paine T.A.
        • Rittiner J.E.
        • Béguin C.
        • Carroll F.I.
        • Roth B.L.
        • et al.
        Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats.
        Psychopharmacology (Berl). 2010; 210: 263-274
        • Tejeda H.A.
        • Counotte D.S.
        • Oh E.
        • Ramamoorthy S.
        • Schultz-Kuszak K.N.
        • Bäckman C.M.
        • et al.
        Prefrontal cortical kappa-opioid receptor modulation of local neurotransmission and conditioned place aversion.
        Neuropsychopharmacology. 2013; 9: 1770-1779
        • Mallikarjun P.K.
        • Lalousis P.A.
        • Dunne T.F.
        • Heinze K.
        • Reniers R.L.
        • Broome M.R.
        • et al.
        Aberrant salience network functional connectivity in auditory verbal hallucinations: A first episode psychosis sample.
        Transl Psychiatry. 2018; 8: 69
        • Goll Y.
        • Atlan G.
        • Citri A.
        Attention: The claustrum.
        Trends Neurosci. 2015; 38: 486-495

      Linked Article

      • The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence
        Biological PsychiatryVol. 86Issue 7
        • Preview
          Schizophrenia is a debilitating mental illness that affects approximately 1% of the world’s population. Despite much research in its neurobiology to aid in developing new treatments, little progress has been made. One system that has not received adequate attention is the kappa opioid system and its potential role in the emergence of symptoms, as well as its therapeutic potential. Here we present an overview of the kappa system and review various lines of evidence derived from clinical studies for dynorphin and kappa opioid receptor involvement in the pathology of both the positive and negative symptoms of schizophrenia.
        • Full-Text
        • PDF
        Open Access